How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost

About this podcast: 

Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disruptive Innovations to Modernize Clinical Research program. 

More specifically, Ms Thompson discusses how Roche is: 

• Leveraging historical amendment data to enable study teams to understand why protocols are being amended
• Utilizing a visual data science platform to generate insights from data to make better data-driven decisions
• Applying retrospective learning into current protocols to curb the need for amendments
• Building in business value 

For more information, go to DPHARMconference.com.

Liz Thompson

Global Development Leader, Senior Clinical Development Scientist

Roche

Liz Thompson

Global Development Leader, Senior Clinical Development Scientist
Roche

Liz Thompson is a Global Development Leader and R&D Excellence Execution Lead at Roche Products Ltd, with over 30 years of experience in drug development. At Roche, she spearheads the Study Design and Protocol Optimization initiative, leading to significant cost and time savings. Thompson has been instrumental in developing numerous new medicines, including treatments for rheumatoid arthritis and COVID-19. Her career includes leadership roles in biostatistics and clinical development at Roche, GlaxoSmithKline, and AstraZeneca.